• Ataraxis AI’s technology is 30% more accurate than the current standard for breast cancer care, according to the company.
  • The startup raised a $20.4 million Series A led by AIX Ventures, with participation from Thiel Bio, Founders Fund, Floating Point, and others.

Ataraxis AI, a New York-based startup, is revolutionizing cancer treatment by using artificial intelligence to determine whether aggressive treatments like chemotherapy are necessary.

While many AI-driven cancer solutions focus on early detection, Ataraxis aims to predict long-term cancer outcomes, potentially sparing patients from unnecessary chemo and its severe side effects.

The company’s AI model analyzes high-resolution images of cancer cells and has been trained on hundreds of millions of images from thousands of patients. A recent study found that Ataraxis’ technology is 30% more accurate than the current standard for breast cancer care, according to the company.

To support the commercial launch of its first test for breast cancer and expand into other cancers, Ataraxis has raised a $20.4 million Series A round. The funding was led by AIX Ventures, with participation from Thiel Bio, Founders Fund, Floating Point, Bertelsmann, and existing investors Giant Ventures and Obvious Ventures. The company had previously raised a $4 million seed round.

Ataraxis was co-founded by Jan Witowski and Krzysztof Geras, an assistant professor at NYU’s medical school specializing in AI. The startup emerged from stealth last year and is positioning itself as a frontier AI company focused on healthcare applications. Meta’s chief AI scientist, Yann LeCun, serves as an AI adviser.

The company has ambitious goals, aiming for its tests to influence half of all new cancer cases by 2030. It's funding comes amid a broader surge of investment in AI-driven cancer care startups.

In May 2024, Valar Labs raised $22 million to assist patients in determining treatment plans, while Manas AI, co-founded by LinkedIn’s Reid Hoffman, secured $24.6 million for AI-powered drug discovery in January 2025.

Edited by Harshajit Sarmah